MWNA
XGN icon

Marshall Wace North America’s Exagen XGN Stock Holding History

Marshall Wace North America’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,100
Closed -$172K – 1649
2019
Q3 		$172K Buy
+11,100
New +$179K ﹤0.01% 983

Other funds holding XGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Marshall Wace North America's XGN Position: Q4 2019 in Review

Marshall Wace North America sold out of Exagen (XGN) in Q4 2019, closing a stake of 11,100 shares — an estimated $172K sold.

Marshall Wace North America first reported a position in XGN in Q3 2019 and held it in 1 quarter. The position peaked at $172K in Q3 2019. 36 funds tracked by Wall St. Rank hold XGN as of Q4 2019.

  • Marshall Wace North America reported no remaining Exagen position as of Q4 2019 after selling out during the quarter.
  • Marshall Wace North America sold 11,100 Exagen shares in Q4 2019, an estimated $172K.
  • Marshall Wace North America first reported a position in Exagen in Q3 2019 and held it in 1 quarter.
  • Marshall Wace North America's Exagen position peaked at $172K in Q3 2019.
  • 36 funds tracked by Wall St. Rank held Exagen as of Q4 2019.

Based on Marshall Wace North America's 13F filing for Q4 2019, filed 14 Feb 2020.